

**LUPUS AND ALLIED
DISEASES ASSOCIATION, INC.
VERONA, NY**

**FINANCIAL STATEMENTS
AT SEPTEMBER 30, 2025**

C O N T E N T S

Auditor's report	1 - 2
Statements of financial position	3
Statements of activities	4 - 5
Statements of functional expenses	6 - 7
Statements of cash flows	8
Notes to financial statements	9 - 11

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
Lupus and Allied Diseases Association, Inc.
Verona, New York

Report on the Financial Statements

We have audited the accompanying balance sheets of Lupus and Allied Diseases Association, Inc. as of September 30, 2025 and 2024, and the related statements of income, retained earnings, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility


Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a reasonable basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to previously present fairly, in all material respects, the financial position of Lupus and Allied Diseases Association, Inc. as of September 30, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

A handwritten signature in blue ink, appearing to read 'A. Lamirande', with a stylized flourish at the end.

Andrew J Lamirande, CPA. Esq.

January 7, 2026

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENTS OF FINANCIAL POSITION
SEPTEMBER 30, 2025 AND 2024

	<u>2025</u>	<u>2024</u>
ASSETS		
Cash and cash equivalents	\$ 401,768	\$ 546,988
Short-term investments	2,422,915	2,029,934
Accounts receivable, net of bad debts	-	-
Prepaid expenses	-	-
Unconditional promises to give	-	-
Long-term investments	-	-
Contributions receivable	-	-
Property and equipment, net	<u>566</u>	<u>1,044</u>
TOTAL ASSETS	<u><u>\$ 2,825,249</u></u>	<u><u>\$ 2,577,966</u></u>
LIABILITIES		
Accounts payable	\$ -	\$ -
Refundable Advances	-	-
Long-term debt	<u>-</u>	<u>-</u>
TOTAL LIABILITIES	-	-
NET ASSETS		
Unrestricted		
Designated for new program development	-	-
Undesignated	2,825,249	2,577,966
Temporarily restricted	-	-
Permanently restricted	<u>-</u>	<u>-</u>
TOTAL NET ASSETS	<u><u>2,825,249</u></u>	<u><u>2,577,966</u></u>
TOTAL LIABILITIES AND NET ASSETS	<u><u>2,825,249</u></u>	<u><u>2,577,966</u></u>

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF ACTIVITIES
YEAR ENDED SEPTEMBER 30, 2025

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
REVENUES, GAINS, AND OTHER SUPPORT				
Contributions	718,050	-	-	718,050
Special events	208,109			208,109
Investment return	93,817	-	-	93,817
Net assets released from restrictions	-	-	-	-
TOTAL REVENUES, GAINS, AND OTHER SUPPORT	\$ 1,019,976	-	-	1,019,976
EXPENSES				
Direct donor benefit expenses - special events	32,544			32,544
Program services				
Advocacy	75,597	-	-	75,597
Awareness	48,767	-	-	48,767
Education	72,695	-	-	72,695
Research	539,724	-	-	539,724
Supporting services				
Management and general	2,696	-	-	2,696
Special events	670	-	-	670
				-
TOTAL EXPENSES	772,693	-	-	772,693
CHANGE IN NET ASSETS	247,283			247,283
NET ASSETS AT BEGINNING OF YEAR	2,577,966	-	-	2,577,966
NET ASSETS AT END OF YEAR	\$ 2,825,249	\$ -	\$ -	\$ 2,825,249

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF ACTIVITIES
YEAR ENDED SEPTEMBER 30, 2024

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
REVENUES, GAINS, AND OTHER SUPPORT				
Contributions	817,319	-	-	817,319
Special events	202,072			202,072
Investment return	86,141	-	-	86,141
Net assets released from restrictions	-	-	-	-
REVENUES, GAINS, AND OTHER SUPPORT	\$ 1,105,532	-	-	1,105,532
EXPENSES				
Direct donor benefit expenses - special events	29,391			29,391
Program services				
Advocacy	73,871	-	-	73,871
Awareness	54,644	-	-	54,644
Education	50,944	-	-	50,944
Research	562,390	-	-	562,390
Supporting services				
Management and general	2,327	-	-	2,327
Special events	544	-	-	544
				-
TOTAL EXPENSES	774,111	-	-	774,111
CHANGE IN NET ASSETS	331,421			331,421
NET ASSETS AT BEGINNING OF YEAR	2,246,545	-	-	2,246,545
NET ASSETS AT END OF YEAR	\$ 2,577,966	\$ -	\$ -	\$ 2,577,966

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF FUNCTIONAL EXPENSES
YEAR ENDED SEPTEMBER 30, 2025

	<u>Program Services</u>				<u>Supporting Services</u>	
	<u>Advocacy</u>	<u>Awareness</u>	<u>Education</u>	<u>Research</u>	<u>Management and general</u>	<u>Fundraising</u>
Compensation and related expenses: \$	-	\$ -	\$ -	\$ -	\$ -	\$ -
Conference and training	-	-	-	-	-	-
Depreciation	143	143	144	-	24	24
Food	-	-	-	-	-	-
Insurance	803	803	803	-	134	134
Interest	-	-	-	-	-	-
Information technology	812	812	811	-	136	135
Maintenance of equipment	-	-	-	-	-	-
Postage	-	-	-	-	-	-
Printing	-	-	-	-	-	-
Professional fees	583	583	584	-	1,750	-
Grants	-	-	25,000	539,724	-	-
Supplies	-	-	-	-	-	-
Office	2,265	2,265	2,264	-	377	377
Other	-	-	-	-	-	-
Telephone	-	-	-	-	-	-
Transportation	-	-	-	-	-	-
Fuel	-	-	-	-	-	-
Repairs and other	-	-	-	-	-	-
Other	<u>70,991</u>	<u>44,161</u>	<u>43,089</u>	<u>-</u>	<u>275</u>	<u>-</u>
	\$ 75,597	\$ 48,767	\$ 72,695	\$ 539,724	\$ 2,696	\$ 670

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

STATEMENT OF FUNCTIONAL EXPENSES
YEAR ENDED SEPTEMBER 30, 2024

	<u>Program Services</u>				<u>Supporting Services</u>	
	<u>Advocacy</u>	<u>Awareness</u>	<u>Education</u>	<u>Research</u>	<u>Management and general</u>	<u>Fundraising</u>
Compensation and related expense: \$	-	\$ -	\$ -	\$ -	\$ -	\$ -
Conference and training	-	-	-	-	-	-
Depreciation	49	49	49	-	17	9
Food	-	-	-	-	-	-
Insurance	785	786	786	-	131	131
Interest	-	-	-	-	-	-
Information technology	846	846	847	-	141	141
Maintenance of equipment	-	-	-	-	-	-
Postage	-	-	-	-	-	-
Printing	-	-	-	-	-	-
Professional Fees	500	500	500	-	1,500	-
Grants	-	-	-	562,390	-	-
Supplies	-	-	-	-	-	-
Office	1,580	1,580	1,580	-	263	263
Other	-	-	-	-	-	-
Telephone	-	-	-	-	-	-
Transportation	-	-	-	-	-	-
Fuel	-	-	-	-	-	-
Repairs and other	-	-	-	-	-	-
Other	70,111	50,883	47,182	-	275	-
	<u>\$ 73,871</u>	<u>\$ 54,644</u>	<u>\$ 50,944</u>	<u>\$ 562,390</u>	<u>\$ 2,327</u>	<u>\$ 544</u>

See accompanying notes and auditor's report.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

NOTES TO FINANCIAL STATEMENTS
AT SEPTEMBER 30, 2025

NOTE A – NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF ACTIVITIES

Lupus and Allied Diseases Association, Inc. (the Organization) provides public, governmental, and private education and awareness to those interested in lupus and autoimmune diseases throughout the United States. The Organization also supports research and advocates for the advancement of treatment and cures for autoimmune diseases. The Organization is supported primarily through donor contributions, grants, and special events. Approximately 22% and 19% of the Organization's support for the years ended September 30, 2025 and 2024, respectively, came from special events.

BASIS OF ACCOUNTING

The Organization's policy is to prepare its financial statements on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America ("GAAP").

CONTRIBUTED SERVICES

During the years ended September 30, 2025 and 2024, the value of contributed services meeting the requirements for recognition in the financial statements under ASC 958 was not material and has not been recorded. In addition, individuals volunteer their time and expertise to perform a variety of tasks that assist the Organization in their awareness and education efforts. For the year ended September 30, 2025, volunteer hours amounted to 9,879 total hours amounting to \$380,144 valued at the Independent Sector's State Values of Volunteer Time rate of \$38.48 per hour. For the year ended September 30, 2024, volunteer hours amounted to 9,676 total hours amounting to \$360,818.04 valued at the Independent Sector's State Values of Volunteer Time rate of \$37.29 per hour.

INCOME TAXES

The Organization has been classified by the Internal Revenue Service as a corporation described under 501(c)(3) of the Internal Revenue Code ("the Code") as exempt from federal income taxes under section 501(a) of the Code. The Organization is subject to a tax on income from any unrelated business.

CASH AND CASH EQUIVALENTS

For purposes of the statements of cash flows, the Organization considers all highly liquid investments available for current use with an initial maturity of three months or less to be cash equivalents.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

NOTES TO FINANCIAL STATEMENTS
AT SEPTEMBER 30, 2025

CONCENTRATION OF CREDIT RISK

The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and certificates of deposit. The Company places its cash and temporary cash investments with high quality credit institutions. At times such investments may be in excess of the NCUA insurance limit. During the years ended September 30, 2025 and 2024 cash exceeded the federally insured amount by \$2,021,381 and \$1,795,582 respectively.

ESTIMATES

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

PROPERTY AND EQUIPMENT

The Organization capitalizes all property and equipment with a cost of \$500 if purchased or donated as a contribution on the date received, as well as all office equipment that is technological in nature. Donations of property and equipment are recorded as support at their estimated fair market value. Property and equipment are depreciated using the straight-line method.

FINANCIAL STATEMENT PRESENTATION

Under Statement of Financial Accounting Standards (SFAS) No. 117, *Financial Statements of Not-for-Profit Organizations*, the Organization is required to report information regarding its financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets. The Organization has only received unrestricted assets in the year ending September 30, 2025.

CONTRIBUTIONS

Under SFAS No. 116, *Accounting for Contributions Received and Contributions Made*, contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted net assets depending on the absence or existence and nature of any donor restrictions.

LUPUS AND ALLIED DISEASES ASSOCIATION, INC.

NOTES TO FINANCIAL STATEMENTS
AT SEPTEMBER 30, 2025

INVESTMENTS

Under SFAS No. 124, *Accounting for Certain Investments Held by Not-for-Profit Organizations*, investments in marketable securities with readily determinable fair values and all investments in debt securities are reported at their fair values in the statement of financial position.

NOTE B – RESTRICTIONS ON NET ASSETS

The Organization receives contributions from Individuals and Corporations that may be restricted as to use by the Organization determined by the donor. For the year ended September 30, 2025 the Organization was not in receipt of any assets that were restricted either temporarily nor permanently. All assets were received unrestricted as to use by the Organization.

NOTE C – INVESTMENTS

The Organization held certificates of deposit through Americu Credit Union with a maturity date of April 16, 2026 in the amount of \$553,301. These consisted of the following Certificates of Deposit: BOKF National Association with a value of \$235,738, Morton Community Bank with a value of \$85,710, The Middlefield Banking Company with a value of \$101,793, and Western Alliance Bank with a value of \$130,061. The Organization also holds certificates of deposits directly with Americu Credit Union consisting of the following: in the amount of \$119,837 with a maturity date of February 4, 2026, in the amount of \$983,556 with a maturity date of February 12, 2027, in the amount of \$309,362 with a maturity date of January 15, 2026, and in the amount of \$456,859 with a maturity date of March 5, 2026.

NOTE D – PROPERTY AND EQUIPMENT

Property and equipment consist of the following:

	<u>2025</u>	<u>2024</u>
Office Equipment	\$ <u>6,298</u>	\$ <u>6,298</u>
Accumulated Depreciation	<u>(5,732)</u>	<u>(5,254)</u>
	<u>\$ 566</u>	<u>\$1,044</u>

NOTE E – SUBSEQUENT EVENTS

Management has evaluated subsequent events as of January 7, 2026 which is the date the financial statements were available for issuance. No events have been noted.